Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland

Simple Summary Neoadjuvant chemotherapy in HER2-positive breast cancer has become the standard of care. Systemic treatment allows, in many cases, a reduction in the scope of surgical treatment. The aim of our retrospective study was to confirm the efficacy and safety of neoadjuvant chemotherapy in the TCbH-P program. All study patients received six courses of chemotherapy. All patients achieved a reduction in breast tumour size. There were no cardiac complications in any of the patients that prevented the continuation of treatment. A complete pathological response was achieved in 52.9% of patients. No pCR was achieved in any patient over 60 years of age with luminal B HER2-positive cancer, which questions the use of the TCbH-P regimen in this group of patients. Neoadjuvant systemic therapy has now become the standard in early breast cancer management. Chemotherapy in combination with trastuzumab +/- pertuzumab targeted therapy can improve the rates of pathologic complete response (pCR) in patients with HER2-positive breast cancer. Achieving a pCR is considered a good prognostic factor, in particular, in patients with more aggressive breast cancer subtypes such as TNBC or HER2-positive cancers. Furthermore, most studies demonstrate that chemotherapy in combination with trastuzumab and pertuzumab is well tolerated. The retrospective analysis presented here concentrates on neoadjuvant therapy with the TCbH-P regimen, with a particular emphasis on patients over 60 years of age. We analysed the factors affecting the achievement of pCR and present the adverse effects of the applied therapies, opening discussion about optimizing the therapy of older patients with HER-2 positive breast cancer.